First-In-Human Study of COVID-19 Recombinant Protein RBD Booster Vaccine Launches
Dyadic International, Inc. today announced that it has initiated dosing in its Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for the DYAI-100 COVID-19 recombinant protein receptor binding domain booster vaccine candidate.
DYAI-100 is a C1-SARS-CoV-2 recombinant protein RBD vaccine produced using the Company's C1 platform.
Dyadic's lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve the performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets.
Mark Emalfarb, President and CEO of Dyadic, stated in a press release on January 24, 2023, "The results from this first in human clinical trial are expected to accelerate the adoption of the C-1 protein production platform for both vaccine and therapeutic candidates."
"We continue to believe that the use of our industrially proven, highly productive C1 protein production platform to manufacture the recombinant protein antigen used in DYAI-100 represents a novel, highly efficient, and economical approach to rapidly manufacture large quantities of vaccines,” Mr. Emalfarb concluded.